PRESS RELEASES

02/04/09. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences

New York, Feb. 3 /PRNewswire-FirstCall/ -- AngioGenex Inc. is a New York-based biotechnology company that is pioneering the targeting of Id genes and proteins for the discovery and development of anti-angiogenic drugs to treat cancer. Today the Company announced that it presented animal data at two recent scientific meetings that demonstrate the ability of its lead small molecule candidate drug AGX51 to mitigate tumor formation and metastases.

Dr. Robert Benezra, the scientific founder of AngioGenex and Head of the Company's Scientific Advisory Board presented at the Keystone Symposium held January 1-6 in Big Sky, Montana on Angiogenesis and Lymphangiogenesis in Cancer, and Dr. William Garland, the Company's CEO, presented at the PepTalk meeting held January 11-16 in San Diego, California.

Besides AGX51, both speakers also touted the continually emerging importance of Id in the development and progression of cancer and the therapeutic potential of the novel, anti-Id oligonucleotides invented by Dr. Benezra. An initial report on one of these oligonucleotides (AGX1053) appeared last year in Nature Biotechnology 2008; 26: 91-100.

AngioGenex is currently pursuing the preclinical development of its small, patented molecules and oligonucleotides that have potent anti-angiogenic / anti-tumor activity through inhibition of the action of the Id proteins. The Chairman of the Board of AngioGenex, Dr. Richard Salvador, commented that "information accruing on the control of new blood vessel formation into tumors by the Id genes and proteins confirms that drugs that inhibit their activity, such as AGX1053 and AGX51, are the first in a class of new and unique anti-tumor agents. With sufficient funding we plan to have both drugs in man in 9 to 12 months. Our technology offers a potentially more effective and, therefore, a more cost effective anti-angiogenic based therapy for cancer than Avastin, the current leader in this therapeutic area. A new approach is needed because of increasing data-supported concerns about the high cost of Avastin relative to the limited increase in the lifespan of patients gained with its use."

Company Profile: AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise subsequent, substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the Company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the Company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT: Michael Strage, V.P., Corporate Communications, Investor Relations, +1-212-874-6608, Cell: +1-646-642 0701, Fax: +1-212-874-5027, www.AngioGenex.com

11/25/08. AngioGenex Reviews 2008 Achievements and Sets Goals for 2009

NEW YORK, Nov. 25 /PRNewswire-FirstCall/ -- AngioGenex, Inc. (OTC Bulletin Board: AGGX) is a New York-based biotechnology company that leads in targeting Id genes and proteins for the discovery and development of anti-angiogenic drugs to treat cancer. Today the Company announced achievement of its 2008 objectives and its key business goals for 2009.

AngioGenex accomplished a number of important milestones that it set for itself in 2008. In the Research and Development area, the Company completed key pilot studies on novel anti-angiogenic drugs and filed US and foreign patent applications for these agents. A major goal of 2008 was to complete in vivo studies of its lead small molecule drug candidate (AGX51) that would establish the ability of the agent to reduce angiogenesis and to block the growth and metastasis of tumors. According to Dr. Garland, "the data from those studies clearly met this goal and AGX51 has the potential of being the first orally active anti-angiogenic drug that acts by a mechanism not associated with VEGF, the target of Avastin(R), Genentech's blockbuster anti-cancer drug." Moreover, the results demonstrated that mice tolerate AGX51 without any apparent side effects.

In the corporate area, Dr. Richard Salvador, the former global head of Preclinical Development at Hoffmann La Roche, Inc. became Chairman of the Board of Directors and Dr. Garland, who has led the company's drug discovery and development effort, became the CEO.

AngioGenex took important steps to satisfy its near term corporate finance needs and to meet its future capital formation goals. The Company raised a modest amount of equity capital from new and existing shareholders to fund the AGX51 pilot studies, and it retained Griffin Securities LLC, an investment banking firm specializing in early stage biotechnology companies. Working with Griffin, the Company has identified a number of potential corporate partners and investors to support the clinical development of its drugs.

Dr. Garland set out the Company's principal goals for 2009 as follows: "We will conduct additional IND-enabling preclinical studies with AGX51 and present findings from these studies at a major cancer meeting in 2009. The new studies will include expanded safety and additional anti-tumor testing of AGX51 in animals as well as further exploration of the feasibility of use of our companion diagnostic for theranostic purposes. Our goal is to file an IND on AGX51 and to initiate human testing within the next twelve to eighteen months. AngioGenex also plans to recruit at least one new Board member who can help guide the Company's effort to raise additional capital and move its program forward. Raising capital to fund our drug development work will continue to be a central focus of effort in 2009."

Michael Strage, V.P. Corporate Communications, Investor Relations for AngioGenex, Inc., +1-212-874-6608, or mobile, +1-646-642 0701, or fax, +1-212-874-5027

06/10/08. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs

NEW YORK, June 10 (HSMN NewsFeed) -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB ) a New York-based biotechnology company, and the leader in the field of Id targeted anti-angiogenic drugs, announced the appointment of William Garland PhD as Chief Executive Officer. Dr. Garland, formerly with Hoffmann La Roche, Inc., has directed research and development programs for a number of early stage biotech companies such as Centaur Pharmaceuticals, Atairgin Technologies, Lpath Therapeutics, Inc. (LPTN.OB) and Tosk in addition to AngioGenex. He was also instrumental in raising capital for those companies. His career highlights include the successful development of many drugs from discovery through all phases of preclinical and clinical testing, to regulatory approval. Dr. Garland began working with the AngioGenex as a consultant, and later became V.P. Head of Research and Development, Chief Operating Officer, and a member of the company's Board of Directors. He said that: "Since joining the company I have seen the technology progress from identifying the Id proteins as outstanding anti- angiogenic targets, to discovering and patenting proprietary anti-Id agents, including preclinical leads that we are presently testing in vivo."

The Company's product candidates AGX8 and AGX51 are proprietary small molecule inhibitors of the pro-angiogenic Id proteins. Extensive research and numerous major scientific publications by researchers at Memorial Sloan Kettering Cancer Center, led by Dr. Robert Benezra, have proven that the targeted Id proteins are required for the creation of new blood vessels that allow tumors to grow and to metastasize, or spread. The Company discovered these drugs through rational and computational screening approaches and they have shown extremely promising results in both in vitro and in vivo preclinical studies. These data prove that these drug candidates are potent inhibitors of angiogenesis. "Establishing the effectiveness of these molecules in pre-clinical studies is a major milestone in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, acting President and Chairman of the Board, and the former global head of Preclinical Development at Hoffmann La Roche, Inc.

Dr. Garland, who designed and directed the pre-clinical studies, stated that, "These results confirm the "drugability" of the Id proteins as new and promising anti-tumor targets allowing the Company to move forward to bring the anti-Id molecules into the clinic. The data from the in vitro and in vivo studies not only validate our screening strategy but also confirm their mode of action, a major milestone required for IND filing," he added. "The proprietary small molecule inhibitors of the Id proteins are unlikely to cause serious adverse effects in patients since the main function of the Id proteins is to cause blood vessel formation in the developing fetus and they are not required for the normal activity of the vast majority of cells in the adult. Their major function in adults is to promote blood vessel formation into tumors." As for the next steps, "The program is proceeding with a number of additional in vivo studies including tests in tumor models," according to Dr. Garland, "We will be scrutinizing the data from those tests within the next two or three months as we move these drugs towards the clinic."

Company Profile:

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

CONTACT: Michael Strage V.P., Corporate Communications and InvestorRelations of AngioGenex, Inc., +1-212-874-6608, or Cell, +1-646-642-0701 or Fax, +1-212-874-5027, http://www.angiogenex.com, Ticker Symbol: (NASDAQ-OTCBB:AGGX)

01/08/08. Benezra Report in Nature Biotechnology Validates AngioGenex’s Drug Development Platform by Demonstrating Tumor Suppression through Id Protein Inhibition

NEW YORK, January 08, 2008 /PRNewswire-FirstCall/ -- AngioGenex, Inc. , a New York-based biotechnology company, and the category leader in Id targeted drug discovery and development, announced today that a publication in the scientific journal Nature Biotechnology by Dr. Robert Benezra, a Member at Memorial Sloan Kettering Cancer Center and the Head of AngioGenex's Scientific Advisory Board, provided proof that Id proteins are anti-angiogenic targets for cancer prevention. Using a novel biologic molecule targeting the Id-1 protein in mice, Dr. Benezra achieved tumor suppression by blocking blood vessel formation, or angiogenesis. A free abstract and the entire manuscript are available online at http://www.nature.com/nbt/journal/vaop/ncurrent. Additional data in the report demonstrates that Id-Inhibition has a profound impact on tumor metastasis further illustrated the essential role Id plays in the establishment and growth of cancers. According to Benezra: "The effectiveness and low toxicity of these Id1-targeting agents, called PCAOs, appear better in preclinical models than the current anti-VEGF drugs on the market or in clinical development." He concluded that: "The data validates our predictions based on the genetics we and others have performed over the past ten years and moves us much closer toward clinical application."

William Garland, the Head of Research and Development at AngioGenex echoed Benezra's enthusiasm: "AngioGenex is committed to developing drugs that prevent tumor formation and metastasis by inhibiting the formation and/or biological action of Id proteins. Benezra's latest work is a significant advance towards meeting this corporate goal. The work strongly validates the essential nature of the Id genes and proteins as useful cancer targets while also demonstrating that the targets are drugable by conventional means. These important new findings confirm that an anti-Id approach offers a practical method for diminishing angiogenesis and thereby reducing the growth and metastasis of tumors."

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer drugs that prevent the formation of new blood vessels into tumors (angiogenesis) by inhibiting the action of either the Id genes or proteins. The company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. He established that the Id genes are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications. The company's research also shows promise for the treatment of ocular diseases such as diabetic retinopathy and age related macular degeneration.

Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are only limited and unsatisfactory therapies. As a result, anti-angiogenesis therapy has been hailed in medical circles as the first new and promising approach for cancer treatment in many years. "The Id mechanism has been demonstrated in the highest levels of the academic community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread," according to Vice-President Michael Strage. "AngioGenex is in a unique proprietary position to exploit these findings and build a business around the development of pharmaceutical products that can control tumorigenesis and metastasis through Id-inhibition."

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

01/07/08. William Garland Joins AngioGenex’s Board of Directors

NEW YORK, Jan. 7 /PRNewswire-FirstCall/ -- AngioGenex, Inc. AGGX, a New York-based biotechnology company, and the leader in Id targeted anti-angiogenic drug development, announced that its shareholders elected William Garland to the company's Board of Directors at its Annual Meeting. The company also announced that the newly elected Board met and chose founding Director Richard Salvador as its Chairman. As he assumes this new post, Dr. Salvador will continue to serve as acting President and Chief Executive Officer.

"Dr. Garland's knowledge of medicinal chemistry and drug development, as well as his experience with numerous successful early stage biotech companies makes him ideally suited to help guide the company during these pivotal times," said Michael Strage, Vice President for Business Development, who is stepping down as Chairman but will remain on the board. The incoming Chairman added: "After a very productive career at Hoffmann La Roche, Inc., Dr. Garland left to run research and development for a number of successful smaller companies such as Centaur Pharmaceuticals, Atairgin Technologies, Lpath, Inc., Tosk, and AngioGenex. During that time he has managed the successful development of many drugs from pre-clinical studies, through all phases of clinical testing, to regulatory approval. The Board will benefit greatly from his contributions." Following his election, Bill remarked, "The AngioGenex technology remains one of only a handful of truly innovative therapeutic approaches to cancer with breakthrough potential, and I look forward to working with Dick, Michael and the other Board members to accelerate transfer of this technology from the laboratory to the bedside."

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer drugs that prevent the formation of new blood vessels into tumors (angiogenesis) by inhibiting the action of either the Id genes or proteins. The company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. His research established that the Id genes and proteins are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications. The company's research also shows promise for the treatment of ocular diseases such as diabetic retinopathy and age related macular degeneration.

Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are only limited and unsatisfactory therapies. As a result, anti-angiogenesis therapy has been hailed in medical circles as the first new and promising approach for cancer treatment in many years. "The Id mechanism has been demonstrated in the highest levels of the academic community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread," according to Vice-President Michael Strage. "AngioGenex is in a unique proprietary position to exploit these findings as we build a business around the development of pharmaceutical products that can control tumorigenesis and metastasis through Id-inhibition."

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

10/16/07. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for Treatment of Cancer

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major milestones in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc. He further stated that, "the work embodied in this patent establishes the 'drugability' of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic."

According to Dr. William Garland, VP & Head of R&D, "both the in vitro and in vivo studies indicate that our small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active." Further, "inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors."

AngioGenex is currently testing a companion diagnostic that detects low levels of the Id proteins in serum. This diagnostic was developed in collaboration with BioCheck, Inc. of Foster City, California. Preliminary clinical results suggest that it has the potential to detect the presence of Id proteins at an early stage of tumor development allowing early medical intervention; it may also be useful to either follow the course of therapy or to determine whether there is a recurrence of disease. AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

CONTACT: Michael Strage V.P., Corporate Communications and InvestorRelations of AngioGenex, Inc., +1-212-874-6608, or Cell, +1-646-642-0701or Fax, +1-212-874-5027, http://www.angiogenex.com, Ticker Symbol: (NASDAQ-OTCBB:AGGX)

05/03/07. AngioGenex/ BioCheck Collaboration Produces Novel Antibodies, Progress Towards a Cancer Diagnostic and Revenue

FOSTER CITY, Calif. and NEW YORK, May 3 /PRNewswire-FirstCall/ -- AngioGenex, Inc. (OTC:AGGX.OB) announced today that under the leadership of Dr. John Chen, BioCheck Inc., is applying its resources and expertise to the development of a diagnostic for the early detection and prognosis of cancer based on the appearance of Id proteins in blood and tumor tissue. The sale of monoclonal antibodies to the Id proteins prepared by BioCheck has begun to generate revenue and AngioGenex will earn its first milestone payment of $50,000 at the end of the second quarter of 2007. This work is being conducted pursuant to a development and marketing agreement under which AngioGenex has assigned BioCheck exclusive rights to develop and market the cancer diagnostic in return for royalties, with AngioGenex retaining the rights to the antibodies for therapeutic uses. Development of a cancer diagnostic is based on the work of Dr. Robert Benezra, Member of Memorial Sloan Kettering Cancer Institute (NYC), who demonstrated that the actions of the Id genes and Id proteins are required for the growth and spread of tumors in animals. He proved that even a partial loss of Id gene function prevents the formation of a network of blood vessels (angiogenesis) that supplies the tumor with nutrients needed for survival and growth. The clinical use of agents that block angiogenesis has been hailed by oncologists as the first new and promising approach for the treatment of cancer in a decade.

Dr. Chen has over 30 years of experience in diagnostics. Prior to forming BioCheck, he co-founded Medix Biotech 1983) that was acquired by Genzyme Co. in 1992, and later founded Rapid Diagnostics (1998) that was acquired by ICN Pharmaceuticals in 2002. While involved in the development of many monoclonal antibodies and diagnostics, he is best known for creation of the Early Pregnancy Test (EPT). Dr. Chen commented that "the work of Dr. Benezra is compelling and provides a sound scientific basis for the development of a diagnostic that could not only be useful for the early detection of cancer but could also serve as a biomarker to follow therapy and to detect recurrence of disease." According to Richard Salvador, CEO of AngioGenex: "the development of a diagnostic for the Id proteins will add an important dimension to our clinical program in cancer. And added; "we are fortunate to work with Dr. Chen and his team who provide outstanding technical expertise in antibody development and a proven ability to create and move diagnostic programs to the market place."

AngioGenex is an early stage biotechnology company, discovering and developing compounds potentially useful for the diagnosis and treatment of cancer. The Company's primary goal is to test newly discovered anti-cancer drugs in man that act by inhibiting either the Id genes or Id proteins. The use of the BioCheck diagnostic to detect the presence of an Id containing tumor followed by treatment with an AngioGenex anti-Id drug is expected to provide early and selective targeted therapy for cancer patients. To date, Id proteins have been found in all major tumors tested including breast and colon. Anti-Id drugs also offer opportunities for the treatment of many non- cancer diseases in which abnormal growth of blood vessels is an important part of the underlying cause as in age related macular degeneration, severe arthritis and endometriosis.

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that required clinical trials will be successful, necessary regulatory approvals will be obtained, or the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of therapeutic drugs, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on research grants, current and future competition, and other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

03/07/07. AngioGenex Listing Approved-Trading Under Symbol AGGX.OB

NEW YORK, March 7 /PRNewswire-FirstCall/ -- AngioGenex, Inc. a New York based biotechnology company, has been approved for trading on the NASDAQ OTC market under the symbol AGGX.OB. "This completes the Company's transition from a private company into a full reporting, publicly traded company," according to President and CEO Richard Salvador. He explained that, "this important step provides investors with liquidity and improves the Company's access to capital for its drug development programs."

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer drugs that prevent the formation of new blood vessels into tumors (angiogenesis) by inhibiting the action of either the Id genes or proteins. The Company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. He established that the Id genes are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications. The Company's research also shows promise for the treatment of ocular diseases such as diabetic retinopathy and age related macular degeneration.

In addition to its drug development program, the Company and its partner BioCheck, Inc. of Foster City, California, have produced a highly sensitive Id-based blood assay that shows promise for use as a cancer diagnostic and prognostic. The Company is also conducting investigations to determine how blocking the action of the Id genes and proteins can be useful to treat several non-cancer diseases in which abnormal and excessive growth of blood vessels is an important part of the underlying pathology. The Company's ophthalmology group has developed evidence in animal models that the absence of the Id genes reduces the growth of blood vessels into the eye. This process and the ensuing complications damage eyesight in ocular diseases such as diabetic retinopathy and age related macular degeneration. The Company's plans include developing small molecule and anti-sense/siRNA products for these growing markets.

The Company has agreements with MSKCC granting worldwide exclusive licenses and patents pending for: (1) use of the Id genes and proteins as therapeutic targets, (2) the proprietary mouse that lacks the Id genes (knockout animal), and (3) the use of Id measurements to develop a diagnostic and prognostic test for cancer. The collaboration with BioCheck, Inc. has led to patent applications related to the diagnostic and the monoclonal antibodies to the Id proteins. This intellectual property and AngioGenex's extensive "know-how" establish the Company's preeminent position to develop Id based pharmaceutical products.

For press and other inquiries contact: Michael Strage V.P. 425 Third Avenue Corporate Communications Suite 902 Investor Relations New York, NY 10017, Phone: ( 212) 874-6608 Cell: (646) 642 0701 Fax: (212) 874-5027, Web site: http://www.angiogenex.com/

01/19/06. AngioGenex, Inc., Becomes a Public Company.

NEW YORK, Feb. 1 (HSMN NewsFeed) -- AngioGenex, Inc. a private biopharmaceutical company based in New York, New York, announced that it has merged with eClic, Inc., a reporting public company. On a diluted basis existing AngioGenex shareholders will own 94% of the post-merger company. "The merger into a full reporting public company should improve the terms upon which we will be able to raise the capital necessary to test our Id inhibitor anti-cancer drug leads and diagnostics, and to move our novel technology platform forward," according to President and CEO Richard Salvador. "Once we complete our current round of fund raising, we will submit an application to NASDAQ to have our shares quoted on the OTCBB."

Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are only limited and unsatisfactory therapies. As a result, anti-angiogenesis therapy has been hailed in medical circles as the first new and promising approach for cancer treatment in many years. "The Id mechanism has been demonstrated in the highest levels of the academic community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread, according to Vice-President Michael Strage. "AngioGenex is in a unique proprietary position to exploit these findings and build a business around the development of pharmaceutical products that can control tumorigenesis and metastasis through Id-inhibition."

In addition to its drug development program, the Company and its partner BioCheck, Inc. have produced a highly sensitive Id-based blood assay that shows promise for use as a cancer diagnostic and prognostic. The Company is also conducting investigations to determine how blocking the action of the Id genes and proteins can be useful to treat several non-cancer diseases in which abnormal and excessive growth of blood vessels is an important part of the underlying pathology. The Company's ophthalmology group has developed evidence in animal models that the absence of the Id genes reduces the growth of blood vessels into the eye. This process and the ensuing complications damage eyesight in ocular diseases such as diabetic retinopathy and age related macular degeneration. The Company's plans include developing small molecule and anti-sense/siRNA products for these growing markets.

The Company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. They established that the Id genes are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications.

The Company has agreements with MSKCC granting worldwide exclusive licenses for (1) use of the Id genes and proteins as therapeutic targets, (2) the proprietary mouse that lacks the Id genes (knockout animal), and (3) the use of Id measurements to develop a diagnostic and prognostic test for cancer. The collaboration with BioCheck, Inc. has led to patent applications related to the diagnostic and the monoclonal antibodies to the Id proteins. This intellectual property and AngioGenex's extensive "know-how" establish the Company's preeminent position to develop Id based pharmaceutical products.

For press and other inquiries contact: Michael Strage, Director of Corporate Communications and Investor Relations, AngioGenex, Inc. 825 Third Avenue 40^th floor, New York, NY 10022, Phone: (212) 874-6608, Fax: (212) 874-5027, www.angiogenex.com

04/23/04. AngioGenex and BioCheck Enter into an Agreement to Develop Id-Based Diagnostic Tests for Cancer

New York, NY and Foster City, CA—April 23, 2004—AngioGenex Inc. (AGX) and BioCheck Inc. have entered into an agreement to develop cancer diagnostic and prognostic products based on the Id-gene platform technology licensed exclusively to AGX by the Albert Einstein College of Medicine and the Memorial Sloan Kettering Cancer Center. BioCheck and AGX will apply their resources and expertise to develop diagnostics for early detection and prognosis of cancer based on the measurement of Id-proteins in blood and tumor tissue. A recently approved Phase I SBIR grant will provide seed funding for the collaboration. Partial loss of Id function leads to a profound resistance to the growth and metastasis of tumors in animals due to an inability to develop a supporting network of blood vessels (angiogenesis). In adults, the presence of Id proteins is associated with the formation of tumors.

Under leadership of its President and CEO, Dr. John Chen, BioCheck has developed and marketed widely used diagnostic products. Commenting on this relationship, Dr. William Garland, Chief Operating Officer of AGX stated “I am pleased to report that based on preliminary but promising results in our diagnostic program, we have entered into a Development and Marketing Agreement with BioCheck Inc. In Dr. Chen and his company we have a partner that brings both technical expertise and a proven ability to move diagnostic programs from research and development to successful manufacturing and marketing. The agreement assigns to BioCheck exclusive rights to develop and market diagnostics based on our Id technology. In return, we will receive significant royalties. This partnership has been further solidified by Dr. Chen’s agreeing to become a member of our Scientific Advisory Board.”

In response, Dr. Chen stated “The scientific evidence demonstrating the involvement of the Id genes and proteins in the growth and metastasis of tumors is highly convincing and forms the basis of my interest in pursuing the development of diagnostics for detection of cancer. I am pleased that my company and I can be a part of this very promising approach to the treatment and diagnosis of cancer.”

Dr. Chen was trained as a biochemist and clinical chemist and has over 30 years of research and development experience. Prior to forming BioCheck, he co-founded Medix Biotech (1983) that was acquired by Genzyme Co. in 1992, and later founded Rapid Diagnostics (1998) that was acquired by ICN Pharmaceuticals in 2002. At Medix, Dr. Chen developed the first EPT (Early Pregnancy Test).

AngioGenex Inc. is a biopharmaceutical company engaged in exploiting proprietary technology and knowledge of the actions of the Id genes and proteins to discover and develop drugs and diagnostics useful for the treatment of diseases in which an overgrowth of blood vessels is an important part of the underlying pathology.

Web Site: http://www.angiogenex.com

04/14/04. AngioGenex, Inc. Completes Bridge Financing with Atypical BioVentures Fund

NEW YORK, NY, April 14, 2004. AngioGenex, Inc. (Private) is pleased to announce the completion of an $875,000 convertible bridge note and warrant financing led by Atypical BioVentures Fund. Atypical BioVentures is a newly formed venture capital fund affiliated with Aurora Capital LLC, an investment bank specializing in biotechnology and other life science companies. Richard Salvador, President and CEO of AngioGenex and Bill Garland, Chief Operating Officer, expressed their pleasure that Atypical BioVentures made its first investment in AngioGenex. "We appreciate the validation of our technology and the vote of confidence in our management team that this investment represents.\

AngioGenex, Inc. is engaged in the discovery and development of a new biotechnology platform based on Id genes (inhibitors of differentiation). AngioGenex’s scientific advisory board chairman is Robert Benezra, PhD, a world renowned researcher at the Memorial Sloan Kettering Cancer Center in New York and one of the key scientists in the realm of Id genes. AngioGenex believes that Id genes and their potential gene products represent important targets for cancer treatment and diagnosis. The cancer and opthalmic therapeutic approach is primarily based on the inhibition of angiogenesis. Pro-angiogenic opportunities for cardiovascular disease and other therapeutic areas exist as well.

Atypical BioVentures is a newly formed venture capital fund dedicated to funding and assisting, through active cooperation, life science companies with unique opportunities for commercial success. It is currently managed by Jeff Eliot Margolis, also founder of Aurora Capital LLC.

"Initially we found the depth and breadth of the science, and the experience and dedication of the management team appealing, but further due diligence and a better understanding of the variety of potential product opportunities, the numerous approaches that may be taken and the potential to collaborate commercially and academically at an early stage of development, made this a compelling opportunity for investment.\ explained Margolis.

"It is now the company’s charge to prove the commercial viability of these targets; to build an employee infrastructure, engage with collaborators and contract with key service providers and other stakeholders in the oncology space to bring product opportunities through discovery and development to achieve significant patient benefit and commercial success.\ according to Garland.

AngioGenex is an early stage biotechnology company, discovering and developing compounds potentially useful for the diagnosis and treatment of cancer, as well as for other diseases, that develop and progress utilizing the fundamental biological process known as angiogenesis, or blood vessel formation.

11/03/03. AngioGenex, Inc., Adds Harvard Eye Expert Dr. Patricia D'Amore To Its Scientific Advisory Board.

NEW YORK, N.Y. November 3, 2003-ANGIOGENEX, Inc., the New York-based biotech company, announced today that Patricia A. D'Amore, age 51, currently Professor of Ophthalmology and Pathology at Harvard Medical School, and a Senior Scientist at the Schepens Eye Research Institute, will join the Company as a consultant and a member of its Scientific Advisory Board. Dr. D'Amore will design and supervise AngioGenex's preclinical tests of its ID-based technology for treating ophthamological disorders that involve blood-vessel formation.

"I am very excited about joining AngioGenex," said Dr. D'Amore. "My many years of working on and thinking about angiogenesis has led me to the conclusion that targeting the endothelium itself will be the most specific and effective way to develop directed anti-angiogenic therapies."

Dr. D'Amore received her Ph.D. in Biology from Boston University in 1977 and an M.B.A. from Northeastern University in 1987. Prior to joining Harvard, she was a Postdoctoral Fellow and an Assistant Professor in Biological Chemistry and Ophthalmology at Johns Hopkins Hospital, and an Assistant Professor at Children's Hospital in Boston, where she is currently a Research Associate in Surgery. Dr. D'Amore has served on a variety of national committees including the Cell Biology and Physiology Study Section, and as a Council Member of the North American Vascular Biology Organization and the Chair of the 1999 Gordon Research Conference on Angiogenesis and Microcirculation.

Dr. D'Amore was supported from 1986-1991 by the American Heart Association as an Established Investigator, and is a recipient of both the 1993 Cogan Award for Research in Vision and Ophthalmology and the 1995 Alcon Research Institute Award. While at the Schepens Eye Research Institute, she was awarded the Jules and Doris Stein Professorship for Research to Prevent Blindness in 1999 as was appointed Leader of Dana Farber's Program in Development on Angiogenesis, Invasion and Metastasis.Dr. D'Amore's research focuses on understanding the mechanism of vascular growth and development, particularly the role of growth factors and cell-cell interactions in vascular cell function.

Dr. D'Amore will contribute to formulating strategies for the development of compounds for ocular indications in which AngioGenex currently has an interest, according to Dr. Richard Salvador, President and CEO of AngioGenex.

"We are very pleased that Dr. D'Amore agrees that our technology offers the potential to develop therapies for several serious ocular disorders. Her knowledge and experience as an expert in angiogenesis research will progress the work while adding to AngioGenex's profile in this important field. While encouraging progress has already been made in the application of AngioGenex technology to certain of these diseases, we expect that with Dr. D'Amore's guidance, we will soon be in a position to justify a major ocular program that will attract investors and corporate partners."

AngioGenex, Inc., is engaged in the discovery, acquisition and development of new platform biotechnology and of proprietary pharmaceutical compounds potentially useful for the diagnosis and treatment of cancer, as well as for other diseases, that develop and progress utilizing the fundamental biological process known as angiogenesis.

09/04/02. AngioGenex Acquires Exclusive, Worldwide Rights to Anti-Cancer Technology from the Albert Einstein College of Medicine

NEW YORK, N.Y.— September 4, 2002—AngioGenex Incorporated and the Albert Einstein College of Medicine announced today that AngioGenex has licensed exclusive, worldwide rights to patented inventions to treat and diagnose certain cancers. Antonio Iavarone, MD, the inventor of the technology and a member of AngioGenex Scientific Advisory Board, stated, “I am excited by this first step in the commercialization of my team’s research on Id2 into products to diagnose and treat cancer, particularly the most aggressive childhood cancers of the nervous system.” Dr. Richard Salvador, CEO of AngioGenex, commented, “The acquisition of Dr. Iavarone’s technology will expand the Company’s intellectual property base in the Id area significantly, and we are optimistic that it will enable us to produce important products for the diagnosis and treatment of neuroblastoma and possibly other cancers.”

Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier institutions for medical education, basic research and clinical investigation. Last year alone, the scientific achievements of the faculty resulted in their being awarded more than $120 million in peer-reviewed grants from the National Institutes of Health (NIH). The NIH has designated six major Einstein programs as “Centers of Excellence.” AngioGenex (www.angiogenex.com) is a privately held biotechnology company engaged in the discovery and development of therapeutic and diagnostic products based on Id genes and proteins. Most of the technology licensed to AngioGenex is based on discoveries made by Robert Benezra, PhD, a Member at Memorial Sloan-Kettering Cancer Center, and his research team. His identification of the genes responsible for the formation of blood vessels (angiogenesis) required for the growth and metastasis of tumors provides AngioGenex with new and important anti-cancer targets. Dr. Benezra is the Head of the AngioGenex Scientific Advisory Board.

07/16/02. AngioGenex Enters into a Development Agreement with the Pharmaceutical Division of Kirin Brewery

NEW YORK, N.Y.— August 22, 2000July 14, 2002—AngioGenex Incorporated and the Pharmaceutical Division of Kirin Brewery Limited of Japan today announced that they AngioGenex and the Pharmaceutical Division of Kirin Brewery Co., Ltd. of Japan have entered into a Sponsored Development Agreement. Under the one-year agreement AngioGenex will apply its unique anti-Id (inhibitor of differentiation) technology to create a unique, genetically altered mouse that will be used in research on various human diseases including cancer. Kirin will compensate AngioGenex for providing the genetically altered mouse, and both companies will use the mice in their research programs.

“This agreement provides important validation of the scientific foundation of our young company, and the mouse to be created can be used to confirm the value of the drug discovery targets selected by AngioGenex,” according to Bill Garland, COO at AngioGenex. Maya Tanaka, Director of Business Development of Kirin’s La Jolla based biotechnology division, Gemini Sciences,Katsuhiko Asano, Ph. D., President of the Pharmaceutical Division of Kirin Brewery, stated, “We are very excited about the agreement with Angigenex. This agreement offers us Bbetter animal models of human disease and should allow us to discover new therapeutic drugs.increase the chance of success in the research programs of both companies. The new, genetically altered mice to be provided by AngioGenex constitute an important advance in addressing the need for better tools of this type.”

Kirin is Japan’s foremost beer producer, ranking eighth in the world by sales volume. Kirin’s Pharmaceutical Division The Pharmaceutical Division of Kirin applies its knowledge of biotechnology to the development of advanced pharmaceutical products in the field of renal diseases, cancer, and hematological diseases, and immunologygical and allergy-related diseases. is committed to using biotechnology partnerships to further the development of targets and pharmaceutical products in the fields of hematologic and immunologic diseases and cancer. For more information, please visit the Kirin website at http://www.kirin.co.jp

AngioGenex is a privately held biotechnology company engaged in the discovery, and development of therapeutic and diagnostic products based on a new platform technology associated with Id genes and proteins. Much of the technology is related to discoveries made in the laboratory of Dr. Robert Benezra, at Memorial Sloan-Kettering Cancer Center in New York City, on the requirement of Id genes proteins on the formation of blood vessels needed for tumor growth and metastasis.

For more information, please visit the AngioGenex website at http://www.angiogenex.com

08/22/00. AngioGenex, Inc., Appoints a Senior Executive

NEW YORK, N.Y.- August 22, 2000-AngioGenex, Inc., today announced the appointment of William A. Garland, Ph.D., 56, as Vice President and Chief Operating Officer. As COO, Dr. Garland will be responsible for directing the organization to achieve the goals outlined in the company's strategic plan for the discovery and development of unique products for the diagnosis and treatment of cancer.

From 1994 to 2000, Dr. Garland was Executive Vice President Pharmaceutical Development with Centaur Pharmaceutical, Inc., a Silicon Valley development-stage biopharmaceutical company. At Centaur, he was responsible for progressing three projects from discovery stage to Phase II clinical testing. Dr. Garland helped Centaur grow from 10 to more than 100 employees in 6 years. Prior to joining Centaur, Dr. Garland spent 20 years with Hoffmann-La Roche, Inc. From 1991 to 1994, he was the Senior Director and U.S. Head of International Project Management for Hoffmann La Roche, Inc. Immediately prior to joining AngioGenex, Dr. Garland was Vice President of Scientific Affairs at Atairgin Technologies, Inc., in Irvine, CA, where he was responsible for all R and D activities associated with the company's diagnostic and therapeutic projects.

Dr. Garland holds a B.S. degree in chemistry from the University of San Francisco and a Ph.D. in medicinal chemistry from the University of Washington. He has authored or co-authored over 100 scientific publications, and has had substantial experience in the discovery, development and registration of new therapeutic and diagnostic products.

"We are pleased to welcome an executive with the breadth of knowledge, experience and capability that Dr. Garland brings to the AngioGenex team. This hire completes the first step in our plan to build an organization that uses the best scientific and business practices to exploit our proprietary technology on Id proteins to create products unique in their ability to diagnose and treat cancer," commented Richard A. Salvador, Ph.D., the President and CEO of AngioGenex.